GILD - Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study | Benzinga
Gilead Sciences Inc (NASDAQ: GILD) said it has stopped patient enrollment in BIRCH (Study GS-US-611-6273), a Phase 3 study evaluating the efficacy and safety of obeldesivir compared with placebo in non-hospitalized participants who are at high risk for developing severe COVID-19.
This decision is based on lower-than-expected COVID-19 incidence rates and related hospitalizations or all-cause death by Day 29, which are primary ...